Prentiss Smith & Co’s Zymeworks ZYME Stock Holding History

Prentiss Smith & Co’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,863	Closed	-$230K	–	78
2020 Q4	$230K	Hold	4,863	–	–	0.11%	70
2020 Q3	$227K	Buy	+4,863	New	+$167K	0.12%	65

Other funds holding ZYME

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Prentiss Smith & Co's ZYME Position: Q1 2021 in Review

Prentiss Smith & Co sold out of Zymeworks (ZYME) in Q1 2021, closing a stake of 4,863 shares — an estimated $230K sold.

Prentiss Smith & Co first reported a position in ZYME in Q3 2020 and held it in 2 quarters. The position peaked at $230K in Q4 2020. 125 funds tracked by Wall St. Rank hold ZYME as of Q1 2021.

Prentiss Smith & Co reported no remaining Zymeworks position as of Q1 2021 after selling out during the quarter.
Prentiss Smith & Co sold 4,863 Zymeworks shares in Q1 2021, an estimated $230K.
Prentiss Smith & Co first reported a position in Zymeworks in Q3 2020 and held it in 2 quarters.
Prentiss Smith & Co's Zymeworks position peaked at $230K in Q4 2020.
125 funds tracked by Wall St. Rank held Zymeworks as of Q1 2021.

Based on Prentiss Smith & Co's 13F filing for Q1 2021, filed 21 Jun 2021.